Novartis announced plans to create a flagship manufacturing hub in North Carolina as part of a $23 billion U.S. investment program. The project will add facilities for biologics, sterile packaging, and solid‑dose manufacturing across Durham and Morrisville, expand existing capabilities, and is expected to create roughly 700 direct jobs and over 3,000 indirect roles by 2030. The hub aims to enable end‑to‑end production of key medicines in the U.S., including cell and gene therapies and radioligand therapies. Novartis framed the move as strengthening U.S. supply‑chain resilience and scaling capacity for advanced therapeutics.